These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 10623111)

  • 41. Bugs or drugs, tortoises or hares?
    Jacobs T
    Nat Biotechnol; 2005 Mar; 23(3):293. PubMed ID: 15765079
    [No Abstract]   [Full Text] [Related]  

  • 42. The stampede to convertibles.
    Jacobs T
    Nat Biotechnol; 2003 Aug; 21(8):855. PubMed ID: 12894195
    [No Abstract]   [Full Text] [Related]  

  • 43. When your stock takes a nosedive.
    Jacobs T
    Nat Biotechnol; 2006 Feb; 24(2):144. PubMed ID: 16465152
    [No Abstract]   [Full Text] [Related]  

  • 44. Gary Pisano.
    Pisano G
    Nat Biotechnol; 2011 Mar; 29(3):183. PubMed ID: 21390002
    [No Abstract]   [Full Text] [Related]  

  • 45. 25 top health care stocks. Will they lead the next market boom?
    Kane L
    Med Econ; 2001 Apr; 78(7):126-8, 133-6, 140-2. PubMed ID: 11368040
    [No Abstract]   [Full Text] [Related]  

  • 46. Fake biotech drugs raise concerns.
    Fox JL
    Nat Biotechnol; 2001 Jul; 19(7):603. PubMed ID: 11433258
    [No Abstract]   [Full Text] [Related]  

  • 47. Sumitomo buys Oxford finance.
    Bouchie A
    Nat Biotechnol; 2004 Apr; 22(4):480. PubMed ID: 15085808
    [No Abstract]   [Full Text] [Related]  

  • 48. Biotech round the world: focus on Canada.
    Biotechnol J; 2008 Jul; 3(7):848-51. PubMed ID: 18624341
    [No Abstract]   [Full Text] [Related]  

  • 49. The biotech drug market.
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
    [No Abstract]   [Full Text] [Related]  

  • 50. The 802 million dollars fallacy.
    Hodgson J
    Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
    [No Abstract]   [Full Text] [Related]  

  • 51. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 52. Investors remain wary after first quarter downturn.
    Fletcher L
    Nat Biotechnol; 2002 May; 20(5):413-4. PubMed ID: 11981536
    [No Abstract]   [Full Text] [Related]  

  • 53. Stelios Papadopoulos.
    Papadopoulos S
    Nat Biotechnol; 2011 Mar; 29(3):184. PubMed ID: 21390003
    [No Abstract]   [Full Text] [Related]  

  • 54. Japanese firms broaden investment focus to early biotech.
    Louët S; Sipp D
    Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
    [No Abstract]   [Full Text] [Related]  

  • 55. Paul Keckley.
    Keckley P
    Nat Biotechnol; 2011 Mar; 29(3):185. PubMed ID: 21390004
    [No Abstract]   [Full Text] [Related]  

  • 56. Growing pains for biopharmaceuticals.
    Ashton G
    Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
    [No Abstract]   [Full Text] [Related]  

  • 57. Biotech plummets in 3Q11.
    Yang W
    Nat Biotechnol; 2011 Nov; 29(11):962. PubMed ID: 22068525
    [No Abstract]   [Full Text] [Related]  

  • 58. This Dutchman is flying.
    Watson N
    Fortune; 2003 Jun; 147(13):89-90. PubMed ID: 12827720
    [No Abstract]   [Full Text] [Related]  

  • 59. Investment indicators show US is still ahead.
    Lähteenmäki R; Hodgson J
    Nat Biotechnol; 1998 Feb; 16(2):149-50. PubMed ID: 9487519
    [No Abstract]   [Full Text] [Related]  

  • 60. A new prescription for your portfolio.
    Clifford L; O'Keefe B; Stires D
    Fortune; 2001 Jul; 144(2):74-6, 78, 80. PubMed ID: 11471357
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.